GLP1 receptor (GLP1R)

LUXendins have been developed by Johannes Broichhagen (Max Planck Institute for Medical Research, Heidelberg, Germany and Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany) and David J. Hodson (University of Birmingham). Celtarys has an exclusive worldwide licence for LUXendin commercialization.

Showing all 3 results